Anticancer antifolates: current status and future directions
about
sameAs
Mthfs is an Essential Gene in Mice and a Component of the PurinosomeStructural basis for molecular recognition of folic acid by folate receptorsCritical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathwaysDiscovery of potent pteridine reductase inhibitors to guide antiparasite drug developmentStructure-Based Design of Pteridine Reductase Inhibitors Targeting African Sleeping Sickness and the LeishmaniasesHigh-resolution structures ofTrypanosoma bruceipteridine reductase ligand complexes inform on the placement of new molecular entities in the active site of a potential drug targetStructural Analyses of a Purine Biosynthetic Enzyme from Mycobacterium tuberculosis Reveal a Novel Bound NucleotideA mapping of drug space from the viewpoint of small molecule metabolismResistance of a rodent malaria parasite to a thymidylate synthase inhibitor induces an apoptotic parasite death and imposes a huge cost of fitnessPrinciples of cancer therapy: oncogene and non-oncogene addictionMethotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2dGTP starvation in Escherichia coli provides new insights into the thymineless-death phenomenon.Concentration-dependent processivity of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetase.Tetrahydrobiopterin in cardiovascular health and disease.Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma.Expression, crystallization and preliminary X-ray analysis of the phosphoribosylglycinamide formyltransferase from Streptococcus mutansToward the design of mutation-resistant enzyme inhibitors: further evaluation of the substrate envelope hypothesis.Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles.Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.Disruption of the folate pathway in zebrafish causes developmental defectsA mathematical model of the folate cycle: new insights into folate homeostasis.Inhibition of DNA glycosylases via small molecule purine analogsMthfd1 is a modifier of chemically induced intestinal carcinogenesis.A functional yeast survival screen of tumor-derived cDNA libraries designed to identify anti-apoptotic mammalian oncogenes.Polypurine hairpins directed against the template strand of DNA knock down the expression of mammalian genes.Tetrahydrobiopterin restores diastolic function and attenuates superoxide production in ovariectomized mRen2.Lewis ratsEffect of folic acid on methotrexate induction of sulfotransferases in rats.Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency.A link between impaired purine nucleotide synthesis and apoptosis in Drosophila melanogaster.PharmGKB summary: methotrexate pathway.Pathways of resistance to thymineless death in Escherichia coli and the function of UvrD.Prodrug forms of N-[(4-deoxy-4-amino-10-methyl)pteroyl]glutamate-gamma-[psiP(O)(OH)]-glutarate, a potent inhibitor of folylpoly-gamma-glutamate synthetase: synthesis and hydrolytic stability.Synthesis of (6R)- and (6S)-5,10-dideazatetrahydrofolate oligo-gamma-glutamates: kinetics of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetaseProspective screening of novel antibacterial inhibitors of dihydrofolate reductase for mutational resistanceComparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy.Dysregulation of mitotic machinery genes precedes genome instability during spontaneous pre-malignant transformation of mouse ovarian surface epithelial cells.Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.Folate during antifolate chemotherapy: what we know... and do not know.Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene Regulation.Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed.
P2860
Q21131261-084D6912-B972-46CC-8FBE-9BB0933134BBQ24307935-4A7C7A7D-E711-4200-8443-8E40C18357B5Q24322688-7C82001D-0C9D-4789-A5E2-1913B01656AAQ27649767-43B3033E-C177-42FB-A386-75B796CF52CCQ27658197-0471AC7C-F6B7-4F9B-8D5A-C23D3383E884Q27666140-9C2395E6-8C70-4D07-96CD-B7CBE03FC751Q27674579-65C20AE1-430E-4542-AEF2-55AEC1BA81C9Q28475993-F2045F8C-8B42-4D13-9394-4620B9A16A55Q28478613-608B4AD7-871F-4AA4-B98A-D1ADD71689CAQ29616779-E8F775B3-A772-4E8B-A5BE-D1DC5C1DAFDBQ33521938-5CAD7665-BD6A-40A4-A9CF-6981E2EEB3ECQ33583654-0E2801CD-741D-450E-B7EA-C30FE9CCDF5FQ33586350-57A5234B-8D04-4C4D-BE68-B1E3EF6700EBQ33687812-1984DDC7-0C25-4623-9C85-85EB29242A31Q33713627-E79C7425-F6C3-4DF7-918F-35ABE86EE27DQ33814255-D15AE7C1-66E4-4FF5-B752-00A8A454DE4AQ33815097-15E57C3E-7810-43AB-BA96-2AF7AB691883Q33931249-D5175B15-D4E3-44C4-AE82-1CF8F375EA4AQ33938000-76751BA1-9E62-4634-85A4-5D084C5CCD9EQ34222885-512A479A-B02B-4189-9BDD-E1A6EC940071Q34360712-D323DAA7-81F7-4F9A-A25C-7C79458922E9Q34392708-9553EB6D-DEE7-49C2-84DE-90CEE0EE18D9Q34617243-27698A4F-FD0C-4039-ABEC-212DA60881FCQ34746484-113DB3F1-DE46-49B8-8585-8F5FEE57DA7CQ34956681-A41F6CA5-1A97-48E3-9DE2-6D70F51E46DBQ35001320-AF0025EA-7154-4105-87C0-94E75D90245AQ35025094-7044719D-DD11-4DE8-ACFB-3D81F6CA035CQ35064669-D6090CAA-28F6-4D65-AB48-E0038030E03AQ35065493-CD9EA77C-271D-4238-9A1E-44FFA253FB72Q35115680-D92AF1CF-6BE4-47FA-AB4C-5809114470CEQ35221548-C269CD9C-6ECD-46F2-8262-2A7EA0D15ABEQ35989715-F4B48F2C-EF40-4BDE-BEE5-B185554A2C0EQ36008563-43FBC9C4-B2D1-4498-B389-8708FC5E9817Q36086509-33F674CF-6D2B-4A93-8B0D-7408B8A8D0A7Q36142613-6846C70B-8AF6-42E9-9C5A-B7614910F831Q36179026-1BC84A20-DA21-45CB-8E27-6E57F37C516BQ36209145-9F899DD0-4A94-48F6-B10E-05CD7C2DBEE6Q36278412-2257D711-5655-4C25-AB5D-E95EF1B249FBQ36281621-CFC01BCE-DCF7-4859-8F3E-70C424523B88Q36441443-8C372219-8784-431F-B07A-68E0F45815F2
P2860
Anticancer antifolates: current status and future directions
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Anticancer antifolates: current status and future directions
@ast
Anticancer antifolates: current status and future directions
@en
Anticancer antifolates: current status and future directions
@nl
type
label
Anticancer antifolates: current status and future directions
@ast
Anticancer antifolates: current status and future directions
@en
Anticancer antifolates: current status and future directions
@nl
prefLabel
Anticancer antifolates: current status and future directions
@ast
Anticancer antifolates: current status and future directions
@en
Anticancer antifolates: current status and future directions
@nl
P3181
P356
P1476
Anticancer antifolates: current status and future directions
@en
P2093
John J McGuire
P304
P3181
P356
10.2174/1381612033453712
P407
P577
2003-01-01T00:00:00Z